



Office de la Propriété

Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2405479 C 2010/11/16

(11)(21) **2 405 479**

(12) **BREVET CANADIEN**  
**CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 2001/03/21  
(87) Date publication PCT/PCT Publication Date: 2001/10/04  
(45) Date de délivrance/Issue Date: 2010/11/16  
(85) Entrée phase nationale/National Entry: 2002/09/24  
(86) N° demande PCT/PCT Application No.: SE 2001/000600  
(87) N° publication PCT/PCT Publication No.: 2001/072296  
(30) Priorité/Priority: 2000/03/27 (SE0001071-0)

(51) Cl.Int./Int.Cl. *A61K 31/12*(2006.01),  
*A61K 31/122*(2006.01), *C07C 403/24*(2006.01)

(72) Inventeurs/Inventors:  
ANDERSSON, TOVE, SE;  
PETTERSSON, SVEN, SE

(73) Propriétaire/Owner:  
ASTACAROTENE AB, SE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : PROCEDE D'INHIBITION DE L'EXPRESSION DE CYTOKINES ET DE CHIMIOKINES INFLAMMATOIRES  
(54) Title: METHOD OF INHIBITING THE EXPRESSION OF INFLAMMATORY CYTOKINES AND CHEMOKINES

(57) Abrégé/Abstract:

A method of inhibiting the expression of inflammatory cytokines and chemokines in an animal or man, is disclosed. The method comprises administration to said animal or man of at least one type of xanthophyll, e.g. astaxanthin, in an amount inhibiting the expression of inflammatory cytokines and chemokines in said animal or man. Use of at least one type of xanthophyll, such as astaxanthin, for the preparation of a medicament for the prophylactic and/or therapeutic inhibition of the expression of inflammatory cytokines and chemokines in an animal or man, is described. Further, a commercial package containing a medicament comprising at least one type of xanthophyll, e.g. astaxanthin, and written and/or data carrier instructions for administration to an animal or man of the medicament for the prophylactic and/or therapeutic inhibition of the expression of inflammatory cytokines and chemokines, is disclosed.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number  
WO 01/72296 A1

(51) International Patent Classification<sup>7</sup>: A61K 31/12, C07C 403/24

(21) International Application Number: PCT/SE01/00600

(22) International Filing Date: 21 March 2001 (21.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0001071-0 27 March 2000 (27.03.2000) SE

(71) Applicant (for all designated States except US): ASTAC-AROTENE AB [SE/SE]; Idrottsvägen 4, S-134 40 Gustavsberg (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ANDERSSON, Tove [SE/SE]; Verkstadsgatan 5, S-117 36 Stockholm (SE). PETTERSSON, Sven [SE/SE]; Vårbackvägen 2, S-146 40 Tullinge (SE).

(74) Agents: NILSSON, Brita et al.; Stockholms Patentbyrå Zacco AB, Box 23101, S-104 35 Stockholm (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/72296 A1

(54) Title: METHOD OF INHIBITING THE EXPRESSION OF INFLAMMATORY CYTOKINES AND CHEMOKINES

(57) Abstract: A method of inhibiting the expression of inflammatory cytokines and chemokines in an animal or man, is disclosed. The method comprises administration to said animal or man of at least one type of xanthophyll, e.g. astaxanthin, in an amount inhibiting the expression of inflammatory cytokines and chemokines in said animal or man. Use of at least one type of xanthophyll, such as astaxanthin, for the preparation of a medicament for the prophylactic and/or therapeutic inhibition of the expression of inflammatory cytokines and chemokines in an animal or man, is described. Further, a commercial package containing a medicament comprising at least one type of xanthophyll, e.g. astaxanthin, and written and/or data carrier instructions for administration to an animal or man of the medicament for the prophylactic and/or therapeutic inhibition of the expression of inflammatory cytokines and chemokines, is disclosed.

## Method of inhibiting the expression of inflammatory cytokines and chemokines

The present invention relates to a method of inhibiting the expression of inflammatory cytokines and chemokines in an animal or man, and to the use of a xanthophyll, e.g. astaxanthin, for the preparation of a medicament for the prophylactic and/or therapeutic inhibition of the expression of inflammatory cytokines and chemokines.

### **Background**

The nuclear factor- $\kappa$ B (NF- $\kappa$ B) is a conditionally regulated transcription factor that plays a key role in the expression of a variety of genes involved in inflammation, cell survival, apoptosis, cell differentiation and cancer. It was first identified as a regulator of  $\kappa$  light chain expression in murine B-lymphocytes, but has now been shown to be expressed ubiquitously and to be a master regulator of several important processes. The NF- $\kappa$ B family consists of structurally related proteins of the Rel family, including p50, p52, p65/RelA, c-Rel and RelB (reviewed in Rothwarf and Karin, 1999). In unstimulated cells, NF- $\kappa$ B is bound to the inhibitor protein I $\kappa$ B, which masks the nuclear localisation signal of NF- $\kappa$ B and retains it in the cytoplasm. Activation of the cell with various stimuli initiates signalling pathways involving activation of a whole series of protein kinases. This results in phosphorylation of I $\kappa$ B, targeting the protein for degradation (Rothwarf and Karin, 1999). As a result, the I $\kappa$ B/NF- $\kappa$ B complex dissociates, NF- $\kappa$ B translocates to the nucleus and binds to its cognate sites. Nuclear translocation of NF- $\kappa$ B is activated by various stimuli, including the inflammatory cytokines TNF- $\alpha$  and IL-1, UV-irradiation, mitogens, viruses, bacteria, double stranded DNA, ionizing radiation and hydrogen peroxide, in accordance with the important role played by NF- $\kappa$ B in various tissues (Rothwarf and Karin, 1999).

The functional importance of NF- $\kappa$ B in acute and chronic inflammation is based on its ability to regulate the promoters of a variety of genes. The products of such genes are e.g. cytokines, adhesion molecules and acute phase proteins, which are critical for inflammatory processes (Baeuerle *et al.*, 1995, Shakov *et al.*, 1990, Libermann *et al.*, 1990). These findings are further underlined by the demonstration that mice containing targeted disruptions of the NF- $\kappa$ B subunits p50, RelB and c-Rel are compromised in various aspects of immune function and inflammatory processes (Sha *et al.*, 1995; Weih *et al.*, 1995, Köntgen *et al.*; 1995). Moreover, elevated levels of p65 have been observed in patients with rheumatoid arthritis and Inflammatory Bowel Disease (IBD). A role for NF- $\kappa$ B in inflammation was further established in a recent study, demonstrating that local administration of an antisense

oligonucleotide targeted against the translational start site of NF- $\kappa$ B p65 abrogates established intestinal inflammation in mice (Neurath *et al.*, 1996).

During the last years, it has become evident that redox regulation is an important mechanism that regulates conditional gene expression. Several transcription factors have been shown to be redox-regulated, including NF- $\kappa$ B. One common step in the activation mechanisms that lead to NF- $\kappa$ B translocation has been suggested to involve reactive oxygen species, based on the finding that NF- $\kappa$ B activation can be inhibited by a series of antioxidants (reviewed in Pitette *et al.*, 1997). However, little is known about the pathways that activate and control NF- $\kappa$ B e.g. during oxidative stress.

Due to the involvement of the transcription factor NF- $\kappa$ B in inflammatory processes it could be possible to inhibit the expression of inflammatory cytokines and chemokines by affecting the function of the NF- $\kappa$ B in an animal or human.

### Description of the invention

The present invention provides a method to inhibit the expression of inflammatory cytokines and chemokines in an animal or man.

The method of the invention comprises administration to an animal or man of at least one type of xanthophyll in an amount inhibiting the expression of inflammatory cytokines and chemokines in said animal or man.

Examples of inflammatory cytokines are TNF- $\alpha$  and IL-1, and examples of chemokines are MIP-2, CXC 5 and CXC 6.

The daily doses of the xanthophyll for inhibiting the expression of inflammatory cytokines and chemokines will normally be in the range of 0.01 to 50 mg per kg body weight of an animal or human, but the actual dose will be decided based on the recommendations of the manufacturer of the medicament comprising the xanthophyll.

In an embodiment of the method of the invention the type of xanthophyll is astaxanthin. The astaxanthin may be selected from the group consisting of astaxanthin from a natural source, such as a culture of the alga *Haematococcus sp.*, synthetic astaxanthin and mixtures thereof.

Astaxanthin from other natural sources than algae, such as from fungi and crustaceans, and other xanthophylls as well, are expected to be similarly useful for the purposes of the invention. An advantage of using astaxanthin from algae may be that the astaxanthin exists in a form esterified with fatty acids, which esterified astaxanthin thereby is more stable during handling and storage than free astaxanthin.

20368-730

2a

**SUMMARY OF THE INVENTION**

In one aspect, the invention relates to use, for inhibiting the expression of inflammatory cytokines and chemokines in an animal or man by inhibiting the

5 activation of NF- $\kappa$ B effected by UV-C exposure, of a medicament comprising astaxanthin as the sole active ingredient.

In another aspect, the invention relates to use, in the manufacture of a medicament for inhibiting the expression of inflammatory cytokines and chemokines by inhibiting the activation of NF- $\kappa$ B effected by UV-C exposure, of

10 astaxanthin.

In another aspect, the invention relates to astaxanthin, for use in inhibiting the expression of inflammatory cytokines and chemokines in an animal or man by inhibiting the activation of NF- $\kappa$ B effected by UV-C exposure.

Another aspect of the invention is directed to the use of at least one type of xanthophyll for the preparation of a medicament for the prophylactic and/or therapeutic inhibition of the expression of inflammatory cytokines and chemokines in an animal or man.

In a preferred embodiment the type of xanthophyll is astaxanthin. The 5 astaxanthin may be selected from the group consisting of astaxanthin from a natural source, such as a culture of the alga *Haematococcus sp.*, synthetic astaxanthin and mixtures thereof.

Yet another aspect of the invention is directed to a commercial package containing a medicament comprising at least one type of xanthophyll and written and/or data carrier instructions for administration to an animal or man of the medicament for the 10 prophylactic and/or therapeutic inhibition of the expression of inflammatory cytokines and chemokines.

The medicament preferably comprises astaxanthin, selected from the group consisting of astaxanthin from a natural source, such as a culture of the alga *Haematococcus sp.*, synthetic astaxanthin and mixtures thereof.

15 The commercial package of the invention may additionally contain a water soluble antioxidant, such as glutathione and/or ascorbic acid (vitamin C) and/or a fat soluble antioxidant other than the xanthophyll, such as tocopherol (vitamin E).

The commercial package and/or the medicament comprised by the present invention may comprise additional ingredients which are pharmacologically acceptable 20 inactive or active in prophylactic and/or therapeutic use, such as excipients and flavouring agents.

### Description of the drawing

Fig 1 is a diagram which shows that Astaxanthin inhibits the activation of NF- $\kappa$ B effected by UV exposure. HeLa cells were transfected with a NF- $\kappa$ B-dependent reporter 25 gene and exposed to UV-C 24 hours after transfection. Pretreatment with Astaxanthin was done 3 hours prior to irradiation, where indicated. Cells were harvested and luciferase activity was measured 14-18 hours following exposure. The ratio between Firefly and Renilla luciferase activity is represented as fold activation over the activity in unstimulated control cells. The standard error is based on two identical experiments.

## Experiments

The experiments were conducted in order to show that astaxanthin inhibits the activation of NF- $\kappa$ B effected by UV exposure and thus the expression of inflammatory cytokines and chemokines.

## MATERIALS AND METHODS

### Cell culture

The human fibroblast cell line Hela Tet/off was cultured in MEM alpha medium supplemented with 10% fetal calf serum, penicillin and streptomycin (Gibco Grand Island, NY). The day before transfection, cells were plated on 6 cm dishes in a medium containing 2.5% fetal calf serum. On the day of transfection, the cell culture medium was changed to fresh medium (2.5% fetal calf serum).

### Preparation of Astaxanthin

A stock solution of Astaxanthin was prepared by dissolving synthetic Astaxanthin (Sigma) in 99.6% ethanol. The concentration of Astaxanthin was measured by spectrophotometry, and the absorbance maximum at 474-479 nm was used to calculate the concentration, according to the formula:  $\text{Abs}_{\text{max}}/210$ .

### Plasmids

The 6x $\kappa$ B-Luc plasmid contains a firefly luciferase reporter gene driven by 6 NF- $\kappa$ B binding sites cloned upstream of a TK promoter (Meyer et al. 1993). The pRL-TK plasmid contains a Renilla luciferase reporter gene driven by the TK promoter and is used as a control for transfection efficiency (Promega).

### Transfection, UV irradiation and reporter gene analysis

Plasmid DNA (1 $\mu$ g of the 6x $\kappa$ B-Luc reporter gene plasmid and 200 ng of pRL-TK control plasmid) was added to a mixture of 4  $\mu$ l fuGENE 6 transfection reagent (Boeringer Ingelheim, Germany) and 196  $\mu$ l serum free medium and incubated for 15 min at room temperature, according to the manufacturers protocol. DNA/fuGENE 6 was added to HeLa cells at 50% confluency and the cells were left in a 37°C incubator. 24 hours after transfection, the medium was removed and cells were exposed to UV. For this, a Stratalinker 1800 (Stratagene) emitting a wavelength of 254 nm was used and 10 J/m<sup>2</sup> was applied. The same medium was then added back to the cells, and the cells were incubated at 37°C. Where indicated, cells were pretreated with Astaxanthin for 3 hours, by adding various

concentrations of Astaxanthin to the medium. After addition, the Astaxanthin was left in the medium throughout the experiment.

Extracts were prepared 14-18 hours following exposure, and luciferase assays were performed using components of the luciferase assay system (Promega).

## 5 Results

To analyse whether Astaxanthin has any effect on the activation of NF- $\kappa$ B we performed transient transfection experiments in HeLa cells. NF- $\kappa$ B has been shown to be responsive to UV-irradiation (reviewed in Pitette *et al.*, 1997). Similarly, we demonstrate that exposure of the cells to UV-C induces expression of a transfected NF- $\kappa$ B-dependent reporter gene (Fig. 1). Moreover, pretreatment of the cells with Astaxanthin at the highest concentration repressed this activation almost 3-fold. These data indicate that Astaxanthin has an inhibitory effect on NF- $\kappa$ B, DNA binding activity of NF- $\kappa$ B and/or translocation of the NF- $\kappa$ B across the nuclear membrane by interfering with at the signalling components in the NF- $\kappa$ B activation pathway.

## REFERENCES

5 Rothwarf, D., M. and M. Karin (1999). The NF- $\kappa$ B activation pathway: A paradigm in information transfer from membrane to nucleus. Available at [www.stke.org/cgi/content/full/OC\\_sigtrans;1999/5/re1](http://www.stke.org/cgi/content/full/OC_sigtrans;1999/5/re1).

10 Baeuerle, P., A. and T. Henkel. (1994). Function and activation of NF- $\kappa$ B in the immune system. *Annu. Rev. Immunol.* **12**, 141-179.

15 Shakhov A., N., Collart, M., A., P., Vassalli, S., A., Nedospasov, and C., V. Jongeneel. (1990).  $\kappa$ B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor  $\alpha$  gene in primary macrophages. *J. Exp. Med.* **171**, 35-47.

20 Libermann, T. A and D. Baltimore. (1990) Activation of interleukin-6 gene expression through the NF- $\kappa$ B transcription factor. *Mol. Cell. Biol.* **10**, 237-2334.

25 Sha, W. ,C., Liou, H., C., Tuomanen, E., I. and D., T. Baltimore. (1995). Targeted disruption of the p50 subunit of NF- $\kappa$ B leads to multifocal defects in immune responses. *Cell.* **80**, 321-30.

30 Weih, F., Carrasco, D., Durham, S. K., Barton, D., S., Rizzo, C., A., Ryseck, R., P., Lira, S., A. and R. Bravo. (1995). Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF- $\kappa$ B/Rel family. *Cell* **80**, 331-40.

Köntgen, F., Grumont R., J., Strasser A., Metcalf, D., Li, R., Tarlinton, D. and S. Gerondakis. (1995). Mice lacking the c-rel proto-oncogene exhibit defects in lymphoid proliferation, humoral immunity, and interleukin-2-expression. *Genes Dev.* **9**, 1965-1977.

Neurath, M., F., Pettersson, S., Meyer zum Büschenfelde, K-H. and W. Strober. (1996). Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. *Nature Medicine*. **2**, 998-1004.

5 Piette, J., Piret, B., Bonizzi, G., Schoonbroodt, S., Merville, M-P., Legrand-Poels, S., and V. Bours (1997). Multiple redox regulation in NF-κB transcription factor activation. *Biol. Chem.* **378**, 1237-1245.

10 Meyer, M., Schreck, R., and P., A. Baeuerle. (1993). H<sub>2</sub>O<sub>2</sub> and antioxidants have opposite effects on activation of NF-κappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. *EMBO J.* **12**, 2005-2015.

20368-730

CLAIMS:

1. Use, for inhibiting the expression of inflammatory cytokines and chemokines in an animal or man by inhibiting the activation of NF- $\kappa$ B effected by UV-C exposure, of a medicament comprising astaxanthin as the sole active ingredient.
2. Use of astaxanthin in the manufacture of a medicament for inhibiting the expression of inflammatory cytokines and chemokines by inhibiting the activation of NF- $\kappa$ B effected by UV-C exposure.
- 10 3. The use according to claim 1 or 2, wherein the astaxanthin is selected from the group consisting of astaxanthin from a natural source, synthetic astaxanthin and mixtures thereof.
4. The use according to claim 3, wherein the natural source is a culture of the alga *Haematococcus* sp.
- 15 5. The use according to claim 1 or 2, wherein an amount of astaxanthin to inhibit the expression of inflammatory cytokines and chemokines in said animal or man is 0.01 - 50 mg per kg body weight of said animal or man.
6. The use according to claim 1 or 2, wherein said inflammatory cytokines are TNF- $\alpha$  and IL-1 and said chemokines are MIP-2, CXC 5 and CXC 6.
- 20 7. Astaxanthin, for use in inhibiting the expression of inflammatory cytokines and chemokines in an animal or man by inhibiting the activation of NF- $\kappa$ B effected by UV-C exposure.
8. The astaxanthin according to claim 7, wherein the astaxanthin is selected from the group consisting of astaxanthin from a natural source, synthetic astaxanthin and mixtures thereof.
- 25 9. The astaxanthin according to claim 8, wherein the natural source is a culture of the alga *Haematococcus* sp.

20368-730

9

10. The astaxanthin according to claim 7, wherein said amount inhibiting the expression of inflammatory cytokines and chemokines in said animal or man is 0.01 - 50 mg per kg body weight of said animal or man

5 11. The astaxanthin according to claim 7, wherein said inflammatory cytokines are TNF- $\alpha$  and IL-1 and said chemokines are MIP-2, CXC 5 and CXC 6.

FETHERSTONHAUGH & CO.

OTTAWA, CANADA

PATENT AGENTS




Fig. 1